PLOD1 and polycystic ovary syndrome: Concomitantly, the use of GnRH agonists in follicular phase long-acting long-term plan group and long-term plan group can effectively promote the degree of reproductive endocrine disorder in patients with PCOS, reduce the adverse effects of excessive androgen and LH state on follicular development, coupled with the increase of Gn dose, so a better number of eggs can be obtained, and there are obvious advantages in embryonic development [31–33].